Viagra tablets, film-coated, 100 mg, No. 1
Ingredients
Active ingredient: sildenafil;
1 tablet contains 35.112 mg of sildenafil citrate, equivalent to 25 mg of sildenafil, or
1 tablet contains 70.225 mg of sildenafil citrate, equivalent to 50 mg of sildenafil, or
1 tablet contains 140.450 mg of sildenafil citrate, equivalent to 100 mg of sildenafil;
Inactive ingredients: microcrystalline cellulose; anhydrous calcium hydrophosphate; croscarmellose sodium; magnesium stearate; Opadry® Blue (OY-LS-20921): hypromellose; lactose monohydrate; glycerol triacetate; titanium dioxide (E 171); indigo carmine aluminum lake (E 132); Opadry® Clear (YS-2-19114-A): hypromellose; glycerol triacetate.
Dosage Form
Film-coated tablets.
Main physical and chemical properties: blue film-coated tablets, diamond-shaped with rounded edges, embossed with “Pfizer” on one side and, depending on the dosage, “VGR 25,” “VGR 50,” or “VGR 100” on the other.
Pharmacotherapeutic group
Agents used for erectile dysfunction. Sildenafil. ATC code G04B E03.
Pharmacological Properties
Pharmacodynamics.
Mechanism of action. Sildenafil is an oral medication indicated for the treatment of erectile dysfunction. During sexual arousal, the medication restores impaired erectile function by increasing blood flow to the penis.
The physiological mechanism underlying an erection involves the release of nitric oxide (NO) in the corpora cavernosa during sexual arousal. The released nitric oxide activates the enzyme guanylate cyclase, which stimulates an increase in the level of cyclic guanosine monophosphate (cGMP), which, in turn, causes the smooth muscles of the corpora cavernosa to relax, facilitating blood flow.
Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase 5 (PDE5) in the corpora cavernosa, where PDE5 is responsible for the breakdown of cGMP. Sildenafil’s effect on erections is peripheral in nature. Sildenafil does not exert a direct relaxing effect on isolated human corpus cavernosum tissues, but it potently enhances the relaxing effect of NO on this tissue. When the NO/cGMP metabolic pathway is activated—which occurs during sexual stimulation—sildenafil’s inhibition of PDE5 leads to an increase in cGMP levels in the corpora cavernosa. Thus, sexual arousal is necessary for sildenafil to produce the desired pharmacological effect.
Effect on Pharmacodynamics. In vitro studies have demonstrated that sildenafil is selective for PDE5, which plays an active role in the erectile process. Sildenafil’s effect on PDE5 is more potent than its effect on other known phosphodiesterases. This effect is 10 times more potent than its effect on PDE6, which is involved in phototransduction processes in the retina. When administered at the maximum recommended doses, sildenafil’s selectivity for PDE5 is 80 times greater than its selectivity for PDE1, and is 700 times higher than its selectivity for PDE2, PDEZ, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. In particular, sildenafil’s selectivity for PDE5 is 4,000 times greater than its selectivity for PDEZ—a cAMP-specific isoform of phosphodiesterase involved in the regulation of cardiac contractility.
Pharmacokinetics.
Absorption. Sildenafil is rapidly absorbed. Maximum plasma concentrations are reached within 30–120 minutes (with a median of 60 minutes) after oral administration on an empty stomach. The mean absolute bioavailability following oral administration is 41% (with a range of 25% to 63%). Within the recommended dose range (25 to 100 mg), the AUC and Cmax of sildenafil following oral administration increase proportionally with dose.
When sildenafil is taken with food, the rate of absorption decreases, with a mean prolongation of Tmax to 60 minutes and a mean reduction in Cmax of 29%.
Distribution. The mean steady-state volume of distribution (Vd) is 105 liters, indicating distribution of the drug into body tissues. Following a single oral dose of 100 mg of sildenafil, the mean maximum total plasma concentration of sildenafil is approximately 440 ng/mL (coefficient of variation is 40%). Since the plasma protein binding of sildenafil and its major N-desmethyl metabolite reaches 96%, the mean maximum plasma concentration of free sildenafil reaches 18 ng/mL (38 nmol). The degree of plasma protein binding is independent of total sildenafil concentrations.
In healthy volunteers who received a single 100-mg dose of sildenafil, less than 0.0002% (an average of 188 ng) of the administered dose was detected in the ejaculate after 90 minutes.
Biotransformation. Sildenafil is metabolized primarily by the hepatic microsomal isoenzymes CYP3A4 (major pathway) and CYP2C9 (minor pathway). The major circulating metabolite is formed by N-demethylation of sildenafil. The metabolite’s selectivity for PDE5 is comparable to that of sildenafil, and the metabolite’s activity against PDE5 is approximately 50% of the parent compound’s activity. The plasma concentration of this metabolite is approximately 40% of the plasma concentration of sildenafil. The N-demethylated metabolite undergoes further metabolism, and its half-life is approximately 4 hours.
Elimination. The total clearance of sildenafil is 41 L/h, resulting in a half-life of 3–5 hours. Following both oral and intravenous administration, sildenafil is excreted as metabolites primarily in the feces (approximately 80% of the administered oral dose) and, to a lesser extent, in the urine (approximately 13% of the administered oral dose).
Pharmacokinetics in Special Patient Populations.
Elderly patients. In healthy elderly volunteers (aged 65 years and older), a reduction in sildenafil clearance was observed, resulting in increased plasma concentrations of sildenafil and its active N-demethylated metabolite by approximately 90% compared with the corresponding concentrations in healthy younger volunteers (aged 18–45 years). Due to age-related differences in plasma protein binding, the corresponding increase in the plasma concentration of free sildenafil was approximately 40%.
Renal impairment. In volunteers with mild to moderate renal impairment (creatinine clearance 30–80 mL/min) the pharmacokinetics of sildenafil remained unchanged following a single oral dose of 50 mg. The mean AUC and Cmax of the N-demethylated metabolite increased by a maximum of 126% and 73%, respectively, compared with those in volunteers of the same age without renal impairment. However, due to high interindividual variability, these differences were not statistically significant. In volunteers with severe renal impairment (creatinine clearance below 30 mL/min) sildenafil clearance was reduced, resulting in mean increases in AUC and Cmax of 100% and 88%, respectively, compared with volunteers of the same age without renal impairment. In addition, the AUC and Cmax values of the N-demethylated metabolite were significantly increased by 200% and 79%, respectively.
Hepatic impairment. In volunteers with mild to moderate liver cirrhosis (Child-Pugh classes A and B – Pye classification), sildenafil clearance was reduced, resulting in increased AUC (84%) and Cmax (47%) compared with corresponding values in volunteers of the same age without liver impairment. The pharmacokinetics of sildenafil in patients with severe hepatic impairment have not been studied.
Indications
Viagra® is recommended for men with erectile dysfunction, defined as the inability to achieve or maintain an erection sufficient for successful sexual intercourse.
Sexual stimulation is required for Viagra® to be effective.
Contraindications
- Hypersensitivity to the active ingredient or any of the drug’s excipients.
- Concomitant use with nitric oxide donors (such as amyl nitrite) or nitrates in any form is contraindicated, as sildenafil is known to affect the nitric oxide/cyclic guanosine monophosphate (cGMP) metabolic pathways and potentiates the hypotensive effect of nitrates.
- Concomitant use of PDE5 inhibitors (including sildenafil) with guanylate cyclase stimulators, such as riociguat, is contraindicated, as it may lead to symptomatic hypotension (see the section “Interactions with Other Medications and Other Types of Interactions”).
- Conditions in which sexual activity is not recommended (e.g., severe cardiovascular disorders, such as unstable angina or severe heart failure).
- Loss of vision in one eye due to non-arteritic anterior ischemic optic neuropathy, regardless of whether this condition is related to prior use of PDE5 inhibitors.
- The presence of conditions such as severe hepatic impairment, hypotension (blood pressure below 90/50 mmHg), a recent history of stroke or myocardial infarction, and known hereditary degenerative retinal disorders, such as retinitis pigmentosa (a small number of these patients have genetic disorders of retinal phosphodiesterases), since the safety of sildenafil has not been studied in these patient subgroups.
Drug Interactions and Other Interactions
Effects of other drugs on sildenafil.
In vitro studies. Sildenafil is metabolized primarily by cytochrome P450 (CYP) isoform 3A4 (major pathway) and isoform 2C9 (minor pathway). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance, while inducers of these isoenzymes may increase sildenafil clearance.
In vivo studies. A population pharmacokinetic analysis of clinical trial data demonstrated a reduction in sildenafil clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, and cimetidine). Although no increase in the incidence of adverse events was observed with the concomitant use of sildenafil and CYP3A4 inhibitors, consideration should be given to using an initial dose of 25 mg of sildenafil.
Concomitant use of the HIV protease inhibitor ritonavir, a very potent P450 inhibitor, at steady-state concentrations (500 mg once daily) and sildenafil (a single 100-mg dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1,000% (11-fold) increase in sildenafil plasma AUC. After 24 hours, the plasma level of sildenafil was still approximately 200 ng/mL compared to a level of approximately 5 ng/mL, typical for sildenafil administered alone, which is consistent with ritonavir’s significant effect on a wide range of P450 substrates. Sildenafil does not affect the pharmacokinetics of ritonavir. Given these pharmacokinetic data, the concomitant use of sildenafil and ritonavir is not recommended (see the “Special Considerations” section); in any case, the maximum dose of sildenafil must not exceed 25 mg within a 48-hour period under any circumstances.
Concomitant use of the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at a dose that achieves steady-state concentrations (1,200 mg three times daily), and sildenafil (100 mg as a single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil systemic exposure (AUC). No effect of sildenafil on the pharmacokinetics of saquinavir was observed (see the “Dosage and Administration” section). It is anticipated that more potent CYP3A4 inhibitors, such as ketoconazole and itraconazole, will have a more pronounced effect.
When sildenafil (100 mg as a single dose) was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), an increase in systemic sildenafil exposure of 182% (AUC) was observed. In healthy male volunteers, azithromycin (500 mg daily for 3 days) had no effect on the AUC, Cmax, Tmax, the elimination rate constant, or the terminal half-life of sildenafil or its major circulating metabolite. Cimetidine (a cytochrome P450 inhibitor and a nonspecific CYP3A4 inhibitor) at a dose of 800 mg, when co-administered with sildenafil at a dose of 50 mg in healthy volunteers, resulted in a 56% increase in plasma sildenafil concentrations.
Grapefruit juice is a weak inhibitor of CYP3A4 in the intestinal wall and may cause a moderate increase in sildenafil levels in blood plasma.
A single dose of antacids (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.
Although no specific interaction studies have been conducted with all medications, according to a population pharmacokinetic analysis, the pharmacokinetics of sildenafil were not altered when administered concomitantly with drugs belonging to the group of CYP2C9 inhibitors (tolbutamide, warfarin, phenytoin), the group of CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and thiazide-like diuretics, loop and potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, calcium channel blockers, β-adrenergic receptor antagonists, or CYP450 inducers (such as rifampin, barbiturates).
In a study involving healthy male volunteers, concomitant administration of the endothelin antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9, and possibly CYP2C19) at steady state (125 mg twice daily) and sildenafil at steady state (80 mg three times daily) resulted in a 62.6% and 55.4% reduction in the AUC and Cmax of sildenafil, respectively. Therefore, concomitant use of potent CYP3A4 inducers such as rifampin may result in a more pronounced decrease in sildenafil plasma concentrations.
Nicorandil is a hybrid of a calcium channel activator and a nitrate. The nitrate component makes it likely to interact significantly with sildenafil.
Effects of sildenafil on other medications.
In vitro studies. Sildenafil is a weak inhibitor of cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4 (IC50 > 150 μmol). Since peak plasma concentrations of sildenafil are approximately 1 μmol, the effect of Viagra® on the clearance of substrates of these isoenzymes is unlikely.
There are no data on the interaction of sildenafil with nonspecific phosphodiesterase inhibitors such as theophylline and dipyridamole.
In vivo studies. Since sildenafil is known to affect nitric oxide/cyclic guanosine monophosphate (cGMP) metabolism, it has been established that sildenafil potentiates the hypotensive effect of nitrates; therefore, its concomitant use with nitric oxide donors or with nitrates in any form is contraindicated (see the “Contraindications” section).
Riociguat. Preclinical studies have demonstrated an additive systemic blood pressure-lowering effect when PDE5 inhibitors are used concomitantly with riociguat. Clinical studies have shown that riociguat potentiates the hypotensive effect of PDE5 inhibitors. No positive clinical effect was observed in study participants when PDE5 inhibitors were used concomitantly with riociguat. The concomitant use of riociguat with PDE5 inhibitors (including sildenafil) is contraindicated (see the “Contraindications” section).
Concomitant use of sildenafil and α-adrenergic receptor blockers may lead to symptomatic hypotension in some susceptible patients. This reaction most often occurred within 4 hours after sildenafil administration (see the “Dosage and Administration” and “Special Considerations” sections). In three specific drug interaction studies, the α-adrenergic receptor blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, and 100 mg) were administered concomitantly to patients with benign prostatic hyperplasia whose condition had been stabilized with doxazosin. In these populations, an average additional reduction in blood pressure while the patient was lying down was observed of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, and a mean reduction in blood pressure in the standing position of 6/6 mm Hg, 11/4 mm Hg, and 4/5 mm Hg, respectively. When sildenafil was co-administered with doxazosin in patients whose condition had been stabilized with doxazosin, symptomatic orthostatic hypotension was occasionally reported. These reports described cases of dizziness and near-syncope, but without actual syncope.
No significant interactions were observed with the concomitant use of sildenafil (50 mg) and tolbutamide (250 mg) or warfarin (40 mg), which are metabolized by CYP2C9.
Sildenafil (50 mg) did not prolong bleeding time caused by acetylsalicylic acid (150 mg).
Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers at a mean maximum blood ethanol level of 80 mg/dL.
In patients taking sildenafil, no differences in the adverse event profile were observed compared with placebo when sildenafil was co-administered with classes of antihypertensive drugs such as diuretics, β-adrenergic receptor blockers, ACE inhibitors, angiotensin II antagonists, antihypertensive drugs (vasodilators and centrally acting agents), adrenergic neuron blockers, calcium channel blockers, and α-adrenergic receptor blockers. In a dedicated interaction study involving the concomitant use of sildenafil (100 mg) and amlodipine in patients with hypertension, an additional decrease in systolic blood pressure while lying down of 8 mmHg was observed. The corresponding decrease in diastolic blood pressure was 7 mmHg. In terms of magnitude, these additional reductions in blood pressure were comparable to those observed with sildenafil alone in healthy volunteers (see the “Pharmacological Properties” section).
A 100-mg dose of sildenafil had no effect on the pharmacokinetic parameters of the HIV protease inhibitors saquinavir and ritonavir, which are CYP3A4 substrates.
In healthy male volunteers, administration of sildenafil at steady state (80 mg three times daily) resulted in increases in the AUC and Cmax of bosentan (125 mg twice daily) by 49.8% and 42%, respectively.
Special Considerations for Use
Before starting therapy, a patient’s medical history should be taken and a physical examination performed to diagnose erectile dysfunction and determine its possible causes.
Risk factors for cardiovascular disease. Since sexual activity carries a certain cardiovascular risk, the physician should assess the patient’s cardiovascular status before initiating any treatment for erectile dysfunction. Sildenafil has a vasodilatory effect, which manifests as a mild and transient decrease in blood pressure (see the “Pharmacodynamics” section). Before prescribing sildenafil, the physician should carefully consider whether this effect could adversely affect patients with certain underlying medical conditions, especially when combined with sexual activity. Patients with hypersensitivity to vasodilators include those with left ventricular outflow tract obstruction (e.g., aortic stenosis, hypertrophic obstructive cardiomyopathy) and patients with the rare multisystem atrophy syndrome, one of the manifestations of which is severe autonomic dysregulation of blood pressure.
Viagra® potentiates the hypotensive effect of nitrates (see the “Contraindications” section).
In the postmarketing period, serious adverse cardiovascular reactions have been reported, including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhages, transient ischemic attack, hypertension, and hypotension, which coincided with the use of Viagra®. Most, but not all, of these patients had risk factors for cardiovascular disease. Many of these adverse reactions occurred during or immediately after sexual activity, and only a few occurred shortly after taking Viagra® without sexual activity. Therefore, it is impossible to determine whether the occurrence of these adverse reactions is directly related to risk factors or whether they are caused by other factors.
Priapism. Medications for the treatment of erectile dysfunction, including sildenafil, should be prescribed with caution to patients with anatomical deformities of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) or to patients with conditions that predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).
Cases of prolonged erection and priapism have been reported since the drug was introduced to the market. If an erection lasts longer than 4 hours, patients should seek immediate medical attention. Without immediate treatment, priapism can lead to damage to penile tissue and permanent loss of erectile function.
Concomitant use with other PDE5 inhibitors or other medications for the treatment of erectile dysfunction. The safety and efficacy of concomitant use of sildenafil with other PDE5 inhibitors or other medications for the treatment of pulmonary arterial hypertension that contain sildenafil (e.g., Revatio), or with other medications for the treatment of erectile dysfunction has not been studied. Therefore, the use of such combinations is not recommended.
Effects on vision. There have been spontaneous reports of visual disturbances associated with the use of sildenafil and other PDE5 inhibitors (see the “Adverse Reactions” section). Cases of non-arteritic anterior ischemic optic neuropathy, a rare condition, have been reported spontaneously and were reported in an observational study as being associated with the use of sildenafil and other PDE5 inhibitors (see the “Adverse Reactions” section). Patients should be advised that if they experience sudden vision loss, they should stop taking Viagra® and seek immediate medical attention (see the “Contraindications” section).
Concomitant use with ritonavir. Concomitant use of sildenafil and ritonavir is not recommended (see the “Drug Interactions and Other Interactions” section).
Concomitant use with α-adrenergic receptor blockers. Patients taking α-adrenergic receptor blockers should use sildenafil with caution, as this combination may lead to symptomatic hypotension in some susceptible patients. Symptomatic hypotension usually occurs within 4 hours after sildenafil administration. To minimize the potential for postural hypotension in patients taking α-adrenergic receptor blockers, their condition should be stabilized with α-adrenergic receptor blockers before starting sildenafil. Consideration should also be given to using an initial dose of 25 mg (see the “Dosage and Administration” section). In addition, patients should be instructed on how to respond if symptoms of orthostatic hypotension occur.
Effect on Bleeding. Studies of human platelets have shown that, in vitro, sildenafil potentiates the antiplatelet effects of sodium nitroprusside. There is no information regarding the safety of sildenafil use in patients with coagulation disorders or acute peptic ulcers. Therefore, sildenafil should be used in this patient group only after a careful assessment of the benefit-risk ratio.
Excipients. The film coating of the tablets contains lactose. Viagra® should not be used by men with rare hereditary disorders such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
This medication contains less than 1 mmol of sodium (23 mg) per tablet, meaning it is essentially sodium-free. Patients on a low-sodium diet may be informed of this.
Following administration of a 100-mg dose to healthy volunteers, no effects on sperm morphology or motility were observed (see the “Pharmacodynamics” section).
Hearing loss. Physicians should advise patients to stop taking PDE5 inhibitors, including Viagra®, and to seek immediate medical attention in the event of a sudden decrease or loss of hearing. These events, which may also be accompanied by ringing in the ears and dizziness, have been reported in temporal association with the use of PDE5 inhibitors, including Viagra®. It is not possible to determine whether these events are directly related to the use of PDE5 inhibitors or to other factors.
Concomitant use with antihypertensive medications. Viagra® has a systemic vasodilatory effect and may further lower blood pressure in patients taking antihypertensive medications. In a separate drug interaction study involving the concomitant use of amlodipine (5 mg or 10 mg) and Viagra® (100 mg) orally, an average additional decrease in systolic blood pressure of 8 mmHg and in diastolic blood pressure of 7 mmHg was observed.
Sexually transmitted diseases. The use of Viagra® does not protect against sexually transmitted diseases. Consider advising patients on the necessary precautions to protect against sexually transmitted diseases, including human immunodeficiency virus.
Use During Pregnancy or Breastfeeding.
Viagra® is not intended for use by women.
Effect on reaction time when driving or operating machinery.
Viagra® may have a minor effect on the ability to drive or operate machinery. Since cases of dizziness and visual disturbances have been reported during clinical trials of sildenafil, before driving a vehicle or operating other machinery, patients should determine their individual response to Viagra®.
Dosage and Administration
The drug is taken by mouth.
Adults. The recommended dose of Viagra® is 50 mg, taken as needed approximately one hour before sexual activity. Depending on the drug’s effectiveness and tolerability, the dose may be increased to 100 mg or reduced to 25 mg. The maximum recommended dose is 100 mg. The maximum recommended dose should not be taken more than once daily. When Viagra® is taken with food, the onset of action may be delayed compared to when taken on an empty stomach.
Elderly patients. No dose adjustment is necessary for elderly patients (≥ 65 years of age).
Patients with renal impairment. For patients with mild to moderate renal impairment (creatinine clearance 30–80 mL/min), the recommended dose is the same as indicated above in the “Adults” section.
Since sildenafil clearance is reduced in patients with severe renal impairment (creatinine clearance < 30 mL/min), a 25-mg dose should be considered. Depending on the drug’s efficacy and tolerability, the dose may be gradually increased to 50 mg and up to 100 mg if necessary.
Patients with hepatic impairment. Since sildenafil clearance is reduced in patients with hepatic impairment (e.g., cirrhosis), a 25 mg dose should be considered. Depending on the drug’s efficacy and tolerability, the dose may be gradually increased to 50 mg and then to 100 mg if necessary.
Patients taking other medications. If patients are concurrently taking
CYP3A4 inhibitors (with the exception of ritonavir, which is not recommended for use with sildenafil; see the sections “Special Considerations for Use” and “Drug Interactions and Other Interactions”), the use of an initial dose of 25 mg should be considered.
To minimize the potential development of postural hypotension in patients taking α-adrenergic receptor blockers, these patients should be stabilized with α-adrenergic receptor blockers before starting sildenafil. Consideration should also be given to using an initial dose of 25 mg (see the sections “Special Considerations for Use” and “Interactions with Other Medications and Other Types of Interactions”).
Children.
This medication is not indicated for use in individuals under 18 years of age.
Overdose
In clinical trials involving volunteers, adverse reactions following a single dose of sildenafil up to 800 mg were similar to those observed with lower doses of sildenafil but occurred more frequently and were more severe. Administration of sildenafil at a dose of 200 mg did not increase efficacy, but did result in an increase in the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, and visual disturbances).
In case of overdose, standard supportive measures should be taken as necessary. Accelerated clearance of sildenafil during hemodialysis is unlikely due to the drug’s high degree of binding to plasma proteins and the absence of sildenafil excretion in the urine.
Side Effects
The safety profile of Viagra® is based on data from 9,570 patients in 74 double-blind, placebo-controlled clinical trials. The most commonly reported adverse reactions were headache, flushing, dyspepsia, nasal congestion, back pain, dizziness, nausea, hot flashes, visual disturbances, cyanopsia, and blurred vision. Information on adverse reactions from postmarketing surveillance was collected over a period of more than 10 years. Since not all adverse reactions were reported to the sponsor and not all adverse reactions were included in the safety database, the frequency of these reactions cannot be reliably determined.
All clinically significant adverse reactions observed during clinical trials more frequently than with placebo are listed below according to the “System Organ Class” classification and frequency: very common (≥ 1/10), common (≥ 1/100 – < 1/10), uncommon (≥ 1/1,000 – < 1/100), and rare (≥ 1/10,000 – < 1/1,000). Within each frequency group, adverse reactions are listed in order of decreasing severity.
Infectious and infestative disorders.
Uncommon: rhinitis.
Immune system disorders.
Uncommon: hypersensitivity.
Nervous system disorders.
Very common: headache.
Common: dizziness.
Uncommon: drowsiness, hypoesthesia.
Rare: stroke, transient ischemic attack, seizures*, recurrent seizures*, syncope.
Eye disorders.
Common: color vision abnormalities**, visual disturbances, blurred vision.
Uncommon: lacrimation disorders***, eye pain, photophobia, photopsia, ocular hyperemia, visual brightness, conjunctivitis.
Rare: non-arteritic anterior ischemic optic neuropathy*, retinal vascular occlusion*, retinal hemorrhage, arteriosclerotic retinopathy, retinal disorders, glaucoma, visual field defects, diplopia, decreased visual acuity, myopia, asthenopia, floating vitreous opacities, iris disorders, mydriasis, halos around light sources in the visual field, eye swelling, puffiness of the eyes, eye disorders, conjunctival hyperemia, eye irritation, abnormal sensations in the eyes, eyelid swelling, scleral discoloration.
Disorders of the ear and vestibular system.
Uncommon: dizziness, ringing in the ears.
Rare: deafness.
Cardiac disorders.
Uncommon: tachycardia, palpitations.
Rare: sudden cardiac death*, myocardial infarction, ventricular arrhythmia*, atrial fibrillation, unstable angina.
Vascular disorders.
Common: flushing, hot flashes.
Uncommon: hypertension, hypotension.
Respiratory, thoracic, and mediastinal disorders.
Common: nasal congestion.
Uncommon: nosebleeds, sinus congestion.
Rare: sensation of tightness in the throat, swelling of the nasal mucosa, dryness in the nose.
Gastrointestinal disorders.
Common: nausea, dyspepsia.
Uncommon: gastroesophageal reflux disease, vomiting, upper abdominal pain, dry mouth.
Rare: oral hypesthesia.
Skin and subcutaneous tissue disorders.
Uncommon: rash.
Rare: Stevens-Johnson syndrome*, toxic epidermal necrolysis*.
Musculoskeletal and connective tissue disorders.
Uncommon: myalgia, pain in the extremities.
Urinary system disorders.
Uncommon: hematuria.
Reproductive system and breast disorders.
Rare: penile bleeding, priapism*, hematospermia, prolonged erection.
General disorders and administration site conditions.
Uncommon: chest pain, increased fatigue, feeling of heat.
Rare: irritation.
Examination.
Uncommon: increased heart rate.
* Reported only during postmarketing surveillance.
** Color vision abnormalities: chloropsia, chromatopsia, cyanopsia, erythropsia, xanthopsia.
*** Abnormal tear production: dry eyes, decreased tear production, and increased tear production.
The following events were observed in < 2% of patients during controlled clinical trials; a causal relationship has not been established. Reports included events that had a probable association with the use of the drug. Events not listed were mild, and the reports were too vague to be meaningful.
General. Facial edema, photosensitivity reactions, shock, asthenia, pain, sudden fall, abdominal pain, sudden injury.
Cardiovascular system: angina pectoris, AV block, migraine, postural hypotension, myocardial ischemia, cerebral thrombosis, sudden cardiac arrest, ECG abnormalities, cardiomyopathy.
Gastrointestinal disorders: glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, abnormal liver function test results, rectal bleeding, gingivitis.
Blood and lymphatic system disorders: anemia, leukopenia.
Metabolic and nutritional disorders: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemia, hypernatremia.
Musculoskeletal disorders: arthritis, osteoarthritis, tendon rupture, tenosynovitis, bone pain, myasthenia gravis, synovitis.
Nervous system disorders: ataxia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, abnormal dreams, decreased reflexes.
Respiratory system disorders: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, increased salivation, worsening of cough.
Skin disorders: hives, herpes, itching, sweating, skin ulcers, contact dermatitis, exfoliative dermatitis.
Sensory disorders: sudden hearing loss or impairment, ear pain, hemorrhage in the eye, cataracts, dry eyes.
Urogenital disorders: cystitis, nocturia, increased urinary frequency, breast enlargement, urinary incontinence, ejaculatory dysfunction, genital edema, anorgasmia.
Postmarketing experience. The following adverse reactions have been identified since the drug was marketed. Since such reactions are reported on a voluntary basis and reports come from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship with exposure to the drug. These events were noted due to their severity, frequency of reporting, the absence of a clear alternative cause, or a combination of these factors.
Cardiovascular and cerebrovascular events. Serious cardiovascular, cerebrovascular, and vascular events have been reported, including cerebrovascular hemorrhage, subarachnoid and intracerebral hemorrhage, and pulmonary hemorrhage, which were temporally associated with the use of Viagra®. Most, but not all, of these patients had cardiovascular risk factors. Many of these events were reported to have occurred during or immediately after sexual activity, and a few events occurred immediately after taking Viagra® without sexual activity. Other events occurred within the following hours or days after taking Viagra® and engaging in sexual activity. It is impossible to determine whether these events are related to the use of the drug, to sexual activity, to pre-existing risk factors, to a combination of these factors, or to other factors.
Cardiovascular and Lymphatic Systems: Vaso-occlusive Crisis. In a small, prematurely terminated study of Revatio (sildenafil) involving patients with pulmonary arterial hypertension secondary to sickle cell anemia, the occurrence of vaso-occlusive crises requiring hospitalization was reported more frequently with sildenafil than with placebo. The clinical significance of this information for patients using Viagra® to treat erectile dysfunction is unknown.
Nervous system: anxiety, transient global amnesia.
Sensory disturbances.
Hearing. Since the drug’s introduction to the market, cases of sudden hearing loss or impairment have been reported, temporally associated with the use of Viagra®. In some cases, underlying medical conditions and other factors that could have contributed to the development of auditory adverse reactions were reported. In many cases, information regarding follow-up medical observation is lacking. It is not possible to determine whether these events are directly related to the use of Viagra®, to existing risk factors for hearing loss, to a combination of these factors, or to other factors.
Vision: temporary vision loss, redness of the eyes, burning sensation in the eyes, increased intraocular pressure, retinal edema, retinal vascular disease or hemorrhage, vitreous detachment.
Since the drug’s introduction to the market, there have been rare reports of non-arteritic anterior ischemic optic neuropathy, which causes vision loss, including permanent vision loss, that were temporally associated with the use of PDE5 inhibitors, including Viagra®. Many, but not all, of these patients had anatomical or vascular risk factors for non-arteritic anterior ischemic optic neuropathy, including (but not limited to) the following: a low cup-to-disc ratio (congestive optic disc), age over 50 years, hypertension, coronary artery disease, hyperlipidemia, and smoking. It is not possible to determine whether these events are directly related to the use of PDE5 inhibitors, to pre-existing anatomical or vascular risk factors, to a combination of all these factors, or to other factors.
Reporting of Suspected Adverse Reactions. Reporting of suspected adverse reactions after the drug’s approval is of great importance. This allows for continuous monitoring of the benefit-risk profile associated with the use of this drug. Physicians should report any suspected adverse reactions in accordance with legal requirements.
Shelf life
5 years.
Storage Conditions
Store in the original packaging at a temperature not exceeding 30 °C. Keep out of the reach of children.
Packaging
25 mg: 4 tablets per blister pack, 1 blister pack per cardboard box.
50 mg: 1 or 4 tablets per blister pack, 1 blister pack per cardboard box.
100 mg: 1 or 2 tablets per blister pack, 1 blister pack per cardboard box; 4 tablets per blister pack, 1 or 2 blister packs per cardboard box.
Manufacturer
Fareva Amboise.
Address
Zone Industrielle, 29 route des Industries, 37530 Poce-sur-Cisse, France /
Zone Industrielle, 29 route des Industries, 37530 Poce-sur-Cisse, France.
Similar products
Products from the same category









